Katzung Chapter 28: Pharmacological Management of Parkinsonism and Other Movement Disorders and Chapter 29: Antipsychotic Agents and Lithium

Chlorpromazine

First generation typical antipsychotic, dopamine antagonist

Haloperidol

First generation typical antipsychotic, dopamine antagonist

Thioridazine

First generation typical antipsychotic, dopamine antagonist, may cause QT prolongation

Clozapine

Second generation atypical antipsychotic, dopamine and serotonin antagonist, may cause agrunilocytosis and requires WBC counts

Risperidone

Second generation atypical antipsychotic, dopamine and serotonin antagonist

Quetiapine

Second generation atypical antipsychotic, dopamine and serotonin antagonist

Olanzepine

Second generation atypical antipsychotic, dopamine and serotonin antagonist

Aripiprazole

Second generation atypical antipsychotic, dopamine and serotonin antagonist

Asenapine

Second generation atypical antipsychotic, dopamine and serotonin antagonist

Palidridone

Second generation atypical antipsychotic, dopamine and serotonin antagonist

Ziprasidone

Second generation atypical antipsychotic, dopamine and serotonin antagonist, may cause QT prolongation

Brexpiprazole

Second generation atypical antipsychotic, dopamine and serotonin antagonist

Cariprazine

Second generation atypical antipsychotic, dopamine and serotonin antagonist

Lurasidone

Second generation atypical antipsychotic, dopamine and serotonin antagonist

Iloperidone

Second generation atypical antipsychotic, dopamine and serotonin antagonist

Anhedonia

Inability to experience pleasure from activities usually found enjoyable

Pramipexole

Antiparkinson, dopamine D3 receptor agonist

Ropinirole

Antiparkinson, dopamine D2 receptor agonist

Selegiline

Antiparkinson, MAO inhibitor (blocks the metabolism of dopamine)

Rasagiline

Antiparkinson, MAO inhibitor (blocks the metabolism of dopamine)

Safinamide

Antiparkinson, MAO inhibitor (blocks the metabolism of dopamine)

Entacapone

Antiparkinson, Catechol-O-methyltransferase inhibitors (blocks the metabolism of dopamine)

Amantadine

Antiparkinson, antiviral, mechanism unknown may potentiate the synthesis, release or reuptake of dopamine

Apomorphine

Potent non-ergoline, D2 receptor agonist, used for temporary relief of akinesia during on/off phenomenon

Reserpine

Causes Parkinson's disease- depletes stores biogenic amines from storage sites including dopamine

Haloperidol and phenothiazines

Causes Parkinson's disease- dopamine antagonists

MPTP

Causes Parkinson's disease- toxic to dopaminergic cells in substantia nigra

Benzotropine

Antiparkison- anticholinergic

Orphenadrine

Antiparkison- anticholinergic

Trihexyphenidyl

Antiparkison- anticholinergic